Traws Pharma

Targeting Critical Threats to Human Health

United States · $146.6M raised

Business Model
B2B
Total Funding
$146.6M
Last Round
$60.0M Private EquityJan 2025
Rounds
3

About

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel oral small molecule therapies targeting respiratory viral diseases and cancer. The company is advancing two investigational antiviral candidates: Ratutrelvir, a ritonavir-independent COVID-19 treatment targeting the main protease, and Tivoxavir marboxil, a single-dose treatment for bird flu and seasonal influenza. Traws Pharma is publicly traded (Nasdaq: TRAW) and focuses on accelerated clinical strategies for vulnerable patient populations.

Summary

Traws Pharma is a Biotech company based in United States. It has raised $146.6M in total across 3 rounds, most recently a $60.0M Private Equity round in Jan 2025. Investors include OrbiMed and Sirenia Capital Management.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityJan 2025
$60.0M

Sign up to see all 3 rounds

Series A through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Traws Pharma on Indexed.vc
<a href="https://indexed.vc/companies/traws-pharma"><img src="https://indexed.vc/api/badge/company/traws-pharma" alt="Traws Pharma on Indexed.vc" width="260" height="76" /></a>